Marta Brambilla
@MartaBrumby
Followers
368
Following
133
Statuses
39
Medical Oncologist, Thoracic cancers
Agrate Brianza, Lombardia
Joined March 2019
RT @MOcchipintiMD: Excited to share our study on ALK-rearranged NSCLC! We report 3 cases of LCNEC transformation post-ALK-TKI, marking the…
0
12
0
RT @DrSanjayPopat: CM816/77T pooled data. 1o=EFS from date surgery. Propensity weighted outcomes. HR=0.61 for peri-operative benefit. Benef…
0
16
0
RT @BiagioRicciutMD: Normalized Membrane Ratio (NMR) of TROP2 by Quantitative Continuous Scoring is predictive of Clinical Outcomes in TROP…
0
27
0
RT @MOcchipintiMD: Happy to share our latest article review on target approach in pleural mesothelioma! Check it out!
0
7
0
RT @PrelajArsela: Abstracts wanted! Showcase your work in AI for oncology and research by presenting an abstract for the 2nd edition of the…
0
24
0
RT @achillebott91: It was a great honor for me today to discuss the PEANUT trial update to #AIOM. Pembrolizumab + nab-paclitaxel confirmed…
0
12
0
A “small” sample of a great group from @IstTumori at #AIOM23! Good luck to @MOcchipintiMD as a new member of Working Group AIOM Giovani 🍀 looking forward to seeing your ideas put into practice 😊
A beautiful pic of #INT at #AIOM23 and good luck to @MOcchipintiMD for starting his new course in #aiomgiovani working group. Bravo! 🎉
0
0
8
Beyond first line in #NSCLC WT: a real pleasure to listen to @GLoRussoMD_PhD talking about future perspectives in this tough and challenging topic at #AIOM23 @AIOMtweet
0
3
13
A very RELEVENT option for metastatic thymic carcinoma! Excellent work of Italian #Tymenetwork and brilliant talk by @LaClaudia83
Rare thoracic tumors🫁 have also place at #ESMO2023. RELEVENT study in metastatic thymic carcinoma in 35 out of 52 tested ramucirumab plus paclitaxel carboplatine report promising RR 80% by INV but 58% by central, good PFS and OS with 49% grade 3 TEAEs. New option in 1st line😊
0
1
7
A step forward to better understand epithelioid pleural #mesothelioma. Metabolism and inflammation pathways may play a role in defining prognosis of this rare cancer @MOcchipintiMD
Transcriptomic analysis to better predict prognosis of epithelioid malignant #pleuralmesothelioma Well done @MOcchipintiMD
@IstTumori
0
0
8
Is there a place for #immunotherapy in #NSCLC with novel molecular alterations? Spoiler: they are not all the same
Find out more about the role of IO in NSCLC with novel driver alterations. 👉 Our latest pubblication just out in @ClinicalLung
@MartaBrumby
@teresa_beninato
0
2
9
RT @fedenichetti: #MolecularTumorBoard is key to optimize #PrecisionOncology: from #NextGenerationSequencing to new therapies, MTB increase…
0
2
0
RT @giusvisc: 🔹Networking and multidisciplinarity for treatment of thymic malignancies 🗓️ Wed 10 May 5pm ➡️ Sign up at
0
3
0
RT @mazzeolaure: Brilliant presentation @PrelajArsela ✨️ for this great international Congress #ArtificialIntelligence for #oncology 🎯. Mor…
0
4
0
RT @CharlesSwanton: Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillH…
0
1K
0
RT @saramanglaviti: Which role for 1st line single agent #IO in PDL1 low-neg #NSCLC? Take a look to our #PEOPLE trial results @ESMO_Open…
0
8
0
RT @giusvisc: pleased to moderate session focused on cancer in young adults at @AIOMtweet congress: barriers to conducting clinical trials,…
0
7
0
RT @spagnole1: Wondeful presentation by @PrelajArsela on Artificial Intelligence in oncology: open your mind to a new frontier of personali…
0
6
0